The global glutamate carboxypeptidase 2 market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Glutamate Carboxypeptidase 2 is an enzyme that is encoded by the FOLH1 (folate hydrolase 1) gene in humans and is a class 2 membrane glycoprotein. It is used for the diagnosis and treatment of prostate cancer, and neurological disorder, among others. The major factor contributing to the growth of the market is the increasing prevalence of prostate cancer across the globe.

According to the American Cancer Society, in 2022, there will be an estimated 268,490 new cases of prostate cancer with a mortality rate of 34,500. Additionally, approximately 1 man in 8 is diagnosed with prostate cancer during his lifetime and it is more likely to develop in older men and non-Hispanic black men. Furthermore, approximately 6 cases in 10 are diagnosed in men of age 65 years or older. However, it is rare in men under 40 and the average age of men at diagnosis is about 66. Hence, the increasing prevalence of prostate cancer is driving the demand for GCP 2 treatment, which in turn, is driving the market growth. Furthermore, the market is growing due to new FDA approvals. For instance, in September 2021, Martin Pomper, M.D., PhD, a professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science, received the US Food and Drug Administration’s approval for positron emission tomography (PET) imaging agent targeting the prostate-specific membrane antigen (PSMA). 

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Type

o By Application

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape- Eisai Co Ltd, and Inovio Pharmaceuticals Inc., among others. 

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How players are addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Glutamate Carboxypeptidase 2 Market Report by Segment

By Type 

    • INO-5150

    • E-2072

    • Others

By Application 

    • Prostate Cancer

    • Neuropathic Pain

    • Congnitive Impairment

    • Glioblastoma Multiforme

    • Others

Global Glutamate Carboxypeptidase 2 Market Report by Region

North America

    • United States

    • Canada

Europe

    • UK

    • Germany

    • Italy

    • Spain

    • France

    • Rest of Europe 

Asia-Pacific

    • China

    • India

    • Japan

    • South Korea

    • Rest of Asia-Pacific 

Rest of the World

    • Latin America 

    • Middle East & Africa